MRNAModerna, Inc.

Nasdaq modernatx.com


$ 154.66 $ -0.18 (-0.12 %)    

Thursday, 06-Jun-2024 15:59:57 EDT
QQQ $ 463.32 $ -0.36 (-0.08 %)
DIA $ 389.27 $ 0.74 (0.19 %)
SPY $ 534.63 $ -0.04 (-0.01 %)
TLT $ 93.23 $ -0.12 (-0.13 %)
GLD $ 219.44 $ 1.62 (0.74 %)
$ 154.69
$ 161.05
$ 140.00 x 100
$ 160.00 x 100
$ 152.69 - $ 161.69
$ 62.55 - $ 170.47
4,046,256
na
59.15B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.

 fda-selects-modernas-rare-disease-candidate-for-accelerated-development-program

Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2...

Core News & Articles

- Bloomberg

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

 sp-500-nasdaq-100-jointly-hit-all-time-highs-nvidia-overtakes-apple-as-second-most-valuable-us-company

The S&P 500 and Nasdaq 100 indices closed at record highs due to investor confidence in AI-driven tech sector growth. Magni...

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 whats-going-on-with-novavax-stock

Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look...

 moderna-says-it-is-prepared-to-submit-for-approval-a-covid-vaccine-targeting-either-jn1-or-kp2-variant

- Reuters

 promising-trial-results-show-new-standards-in-cancer-treatment-and-diagnostics-are-on-the-horizon

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a...

 rbc-capital-maintains-outperform-on-moderna-raises-price-target-to-160

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $135 to $160.

Core News & Articles

https://www.youtube.com/watch?v=qCsEbq9SpsM 

 moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-patients

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free an...

Core News & Articles

- Reuters - Reuters 

Core News & Articles

With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination wit...

 needham-reiterates-hold-on-moderna

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION